A hybrid solid-fluorous phase radioiodination and purification platform

A new class of fluorous materials was developed to create a hybrid solid‐solution phase strategy for the expedient preparation and HPLC‐free purification of 125I‐labeled compounds. The system is referred to as a hybrid platform in that it combines solution phase labeling and fluorous solid‐phase purification in one step as opposed to two separate individual processes. Treatment of fluorous arylstannanes coated on fluorous silica with [125I]NaI and the appropriate oxidant made it possible to produce and selectively isolate the nonfluorous radiolabeled products in high purity (>98%) free from excess starting material and unreacted radioiodine. Examples included simple aryl and heterocyclic (click) derivatives, known radiopharmaceuticals including meta‐iodobenzylguanidine (MIBG) and iododeoxyuridine (IUdR), and a new agent with high affinity for prostate‐specific membrane antigen. The coated fluorous silica kits are simple to prepare, and reactions can be performed at room temperature using different oxidants generating products in minutes in biocompatible solutions. A new hybrid solid‐solution phase strategy for the expedient preparation and HPLC‐free purification of 125I‐labeled compounds was developed. Treatment of fluorous arylstannanes coated on fluorous silica with [125I]NaI and the appropriate oxidant made it possible to produce and selectively isolate the radiolabeled products in high purity.